Press release
HER2 therapy market is expected to grow to $33.7 billion by 2034. Crucial Participants: AstraZeneca and Roche
HER2 therapy
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72685
From monoclonal antibodies like trastuzumab and pertuzumab to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan, HER2-targeted drugs have revolutionized treatment outcomes. With rising cancer incidence, strong clinical pipelines, and expanding indications, the HER2 therapy market is positioned for robust growth in the coming decade.
Market Overview
• Market Size 2024: USD 13.8 billion
• Forecast 2034: USD 33.7 billion
• CAGR (2024-2034): 9.4%
Key Highlights:
• Monoclonal antibodies remain the gold standard but ADCs are gaining rapid adoption due to enhanced efficacy.
• Expanding HER2-targeted indications into gastric, colorectal, and non-small cell lung cancers is widening the patient pool.
• Strong clinical pipeline with multiple late-stage trials from leading pharma companies.
• North America and Europe dominate current adoption, while Asia-Pacific is emerging as a high-growth market.
Challenges include therapy resistance, high treatment costs, and access limitations in low-income regions, but innovation continues to drive optimism.
Market Segmentation
By Therapy Type
• Monoclonal Antibodies (Trastuzumab, Pertuzumab, Others)
• Tyrosine Kinase Inhibitors (Lapatinib, Neratinib, Tucatinib)
• Antibody-Drug Conjugates (Trastuzumab Emtansine, Trastuzumab Deruxtecan, Others)
• Combination Therapies
By Indication
• Breast Cancer
• Gastric Cancer
• Colorectal Cancer
• Non-Small Cell Lung Cancer (NSCLC)
• Others
By Route of Administration
• Intravenous (IV)
• Oral
By End User
• Hospitals
• Specialty Oncology Clinics
• Academic & Research Institutes
Segmentation Summary:
Breast cancer remains the dominant indication, but gastric and colorectal cancers are emerging as strong growth drivers. ADCs represent the fastest-growing therapy type, given their improved efficacy and potential to overcome resistance. Hospitals and oncology clinics account for the majority of usage due to specialized treatment requirements.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72685/her2-therapy-market
Regional Analysis
North America
• Largest market with ~45% share in 2024.
• Driven by high cancer prevalence, early adoption of novel HER2 therapies, and strong reimbursement frameworks.
• The U.S. dominates, with widespread use of trastuzumab, pertuzumab, and trastuzumab deruxtecan.
Europe
• Accounts for nearly 30% of the market.
• EMA approvals and strong adoption in Germany, France, and the UK support growth.
• Increasing use of biosimilars is improving affordability.
Asia-Pacific
• Fastest-growing region, CAGR above 11%.
• Rising breast and gastric cancer cases in China, India, and Japan driving demand.
• Expanding healthcare infrastructure and biosimilar adoption fuel accessibility.
Middle East & Africa
• Early-stage adoption with growing oncology infrastructure.
• Limited access to expensive therapies remains a challenge.
Latin America
• Brazil and Mexico lead regional adoption.
• Government initiatives and partnerships improving patient access to targeted therapies.
Regional Summary:
While North America and Europe dominate adoption today, Asia-Pacific is set to be the fastest-growing market by 2034, reshaping the global HER2 therapy landscape.
Market Dynamics
Growth Drivers
• Rising Cancer Prevalence: Increasing incidence of HER2-positive breast and gastric cancers.
• Pipeline Expansion: Ongoing trials expanding HER2 therapies into new cancer types.
• ADC Innovation: New antibody-drug conjugates improving efficacy and overcoming resistance.
• Government & Insurance Support: Reimbursement policies driving accessibility in developed markets.
Key Challenges
• Drug Resistance: Patients often develop resistance to first-line HER2 therapies.
• High Cost: Advanced HER2 therapies, particularly ADCs, remain expensive.
• Access Gaps: Limited adoption in low- and middle-income regions due to affordability issues.
Latest Trends
• Combination Therapies: HER2-targeted drugs increasingly combined with immunotherapies and chemotherapies.
• Biosimilars: Entry of trastuzumab and pertuzumab biosimilars reducing costs.
• Personalized Medicine: Genomic profiling enabling precise treatment selection.
• Expanded Indications: HER2 therapies being tested for rare cancers and earlier lines of therapy.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72685
Competitive Landscape
Key Players
• F. Hoffmann-La Roche Ltd. (Herceptin, Perjeta, Kadcyla)
• AstraZeneca (Enhertu - Trastuzumab Deruxtecan, jointly with Daiichi Sankyo)
• Daiichi Sankyo Co., Ltd.
• Novartis AG
• Pfizer Inc.
• Seagen Inc. (Tucatinib)
• Samsung Bioepis (Biosimilars)
• Amgen Inc.
• Mylan N.V. (Viatris)
• Biocon Biologics Ltd.
• Eli Lilly and Company
• Apotex Inc.
• Celltrion Healthcare
• Merck & Co., Inc.
• Bristol Myers Squibb
Competitive Summary:
The HER2 therapy market is moderately consolidated, with Roche, AstraZeneca/Daiichi Sankyo, and Seagen leading. Roche's legacy portfolio (Herceptin, Perjeta, Kadcyla) still holds significant share, but new entrants like Enhertu (AstraZeneca/Daiichi Sankyo) and Tucatinib (Seagen) are reshaping competition. Biosimilar manufacturers such as Biocon, Samsung Bioepis, and Mylan are expanding access through affordable alternatives.
Conclusion
The HER2 Therapy Market is expected to grow from USD 13.8 billion in 2024 to USD 33.7 billion by 2034, at a strong CAGR of 9.4%. Innovation in ADCs, expansion into gastric and lung cancers, and wider biosimilar adoption will drive future growth.
North America and Europe currently lead, but Asia-Pacific will emerge as the fastest-growing market, reshaping the competitive dynamics.
With newer drug classes, personalized medicine, and strong biosimilar competition, HER2 therapy will remain a cornerstone of oncology care. For pharmaceutical companies, biotech firms, and investors, this market presents a high-value opportunity in the evolving global cancer treatment landscape.
This report is also available in the following languages : Japanese (HER2治療市場), Korean (HER2 치료 시장), Chinese (HER2治疗市场), French (Marché de la thérapie HER2), German (Markt für HER2-Therapien), and Italian (Mercato della terapia HER2), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72685/her2-therapy-market#request-a-sample
Our More Reports:
Medical Waste Management Market
https://exactitudeconsultancy.com/reports/73507/medical-waste-management-market
Total Lab Automation Market
https://exactitudeconsultancy.com/reports/73508/total-lab-automation-market
Chromatography Instrumentation Market
https://exactitudeconsultancy.com/reports/73509/chromatography-instrumentation-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2 therapy market is expected to grow to $33.7 billion by 2034. Crucial Participants: AstraZeneca and Roche here
News-ID: 4204224 • Views: …
More Releases from Exactitude Consultancy
Lipid CMO Market to Reach USD 4.9 Billion by 2034, Growing at 15.0% CAGR
Introduction
Lipids have become a critical component of modern pharmaceutical and biotechnology development, particularly as delivery systems for vaccines, nucleic acid therapies, and innovative biologics. The success of lipid nanoparticles (LNPs) in delivering mRNA COVID-19 vaccines has accelerated global demand for lipid manufacturing expertise, positioning Contract Manufacturing Organizations (CMOs) as essential partners for pharma and biotech firms.
The lipid CMO market is expanding rapidly, supported by increasing investment in gene therapies, RNA-based…
Amnesia Market to Reach USD 8.9 Billion by 2034, Expanding Growing at 6.6% CAGR
Introduction
Amnesia, characterized by partial or complete memory loss, can result from brain injury, stroke, dementia, psychological trauma, substance abuse, or neurodegenerative diseases such as Alzheimer's. While traditionally associated with aging, amnesia is increasingly recognized across all age groups due to traumatic brain injuries, mental health disorders, and substance-related complications.
Growing awareness of neurological health, advances in neuroimaging, and the rise of cognitive rehabilitation therapies are driving innovation in this space. Pharmaceutical…
Pediatric Brain Tumours Market is expected to reach USD 4.8 billion by 2034, wit …
Brain tumours are among the most common solid tumours in children and represent a significant cause of cancer-related mortality in pediatric populations. Conditions such as medulloblastoma, gliomas, ependymomas, and astrocytomas account for the majority of cases. Treatment strategies include surgery, chemotherapy, radiotherapy, and increasingly, targeted therapies and immunotherapies designed to minimize long-term side effects.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72687
Advancements in genomic profiling, molecular diagnostics, and precision…
Pharma Contract Research Organization (CRO) Services Market to Reach USD 193.7 B …
Introduction
The pharmaceutical industry is undergoing a rapid transformation as companies seek to accelerate drug development, reduce costs, and navigate increasingly complex regulatory landscapes. Contract Research Organizations (CROs) have become essential partners, offering specialized expertise in clinical trials, preclinical research, regulatory consulting, and data management.
With rising demand for innovative therapies, biologics, biosimilars, and personalized medicine, outsourcing to CROs is becoming a strategic necessity. These organizations not only provide cost-effective solutions but…
More Releases for HER2
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.
Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with…
